- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Ernexa Therapeutics reports 51% reduction in operating expenses | 1 | Investing.com | ||
| Mi | Ernexa Therapeutics senkt operative Kosten um 51 % | - | Investing.com Deutsch | ||
| Mi | Ernexa Therapeutics Inc.: Ernexa Therapeutics Provides Update on Operational Excellence and Performance | 194 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided... ► Artikel lesen | |
| 13.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 09.07. | Ernexa regains Nasdaq compliance, continues trading on exchange | 2 | Investing.com | ||
| 09.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements | 245 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.07. | Biotech-Unternehmen Ernexa Therapeutics beauftragt Haskell & White als neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| 07.07. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development | 2 | GlobeNewswire (USA) | ||
| 24.06. | Ernexa Therapeutics completes second closing of securities offering | 1 | Investing.com | ||
| 24.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement | 1 | GlobeNewswire (USA) | ||
| 12.06. | Ernexa Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:15 an | 3 | Investing.com Deutsch | ||
| 11.06. | Ernexa Therapeutics registers 57M shares for resale | 2 | Seeking Alpha | ||
| 11.06. | Ernexa Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.06. | Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance | - | RTTNews | ||
| 10.06. | Ernexa Therapeutics announces 1-for-15 reverse stock split | 1 | Investing.com | ||
| 10.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split | 234 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
| BIOXXMED | 0,240 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,991 | -2,44 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem downgraded to NEX | ||
| BIO-GATE | 0,900 | +0,56 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate beschließt und platziert Barkapitalerhöhung | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalerhöhung/Kapitalerhöhung
Bio-Gate AG beschließt und platziert Barkapitalerhöhung
11.09.2025 / 20:04 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,440 | -2,44 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Amie Phinney as Director | Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,302 | -18,82 % | Vaxart, Inc.: Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate | - Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study - SOUTH SAN... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,500 | +2,04 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Sales of High-Purity Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,150 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,654 | -0,61 % | EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Patent
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 9,510 | -3,55 % | Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): BUY | Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH
01.09.2025 / 13:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,265 Euro und damit +7,20 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.